UBS O'Connor’s Axsome Therapeutics AXSM Stock Holding History

UBS O'Connor’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-15,000	Closed	-$46.9K	–	508
2024 Q2	$46.9K	Buy	+15,000	New	+$1.11M	﹤0.01%	450

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS O'Connor's AXSM Position: Q3 2025 in Review

UBS O'Connor sold out of Axsome Therapeutics (AXSM) in Q3 2025, closing a stake of 6,400 shares — an estimated $668K sold.

UBS O'Connor first reported a position in AXSM in Q1 2022 and held it in 12 quarters. The position peaked at $1.85M in Q2 2023. 355 funds tracked by Wall St. Rank hold AXSM as of Q3 2025.

UBS O'Connor reported no remaining Axsome Therapeutics position as of Q3 2025 after selling out during the quarter.
UBS O'Connor sold 6,400 Axsome Therapeutics shares in Q3 2025, an estimated $668K.
UBS O'Connor first reported a position in Axsome Therapeutics in Q1 2022 and held it in 12 quarters.
UBS O'Connor's Axsome Therapeutics position peaked at $1.85M in Q2 2023.
355 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.